3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Generado por agente de IAMarcus Lee
lunes, 10 de febrero de 2025, 4:31 am ET1 min de lectura
ABT--
Investing in healthcare stocks can be a lucrative strategy, given the sector's resilience and growth potential. With a $200 budget, you can diversify your portfolio by allocating funds to three promising healthcare stocks: Pfizer, Abbott Laboratories, and Viking Therapeutics. These companies offer a mix of growth, stability, and potential for significant gains.

1. Pfizer (PFE -0.35%)
Pfizer has taken major steps to turn around its business, including cost-cutting, acquiring and integrating oncology company Seagen, and investing in its internal pipeline. In the recent earnings report, Pfizer reported double-digit quarterly revenue growth, said it was on track to deliver cost savings of $4.5 billion by the end of the year, and reaffirmed its 2025 annual guidance. Pfizer is trading at only 8 times forward earnings estimates, making it an attractive addition to any healthcare portfolio.
2. Abbott Laboratories (ABT 0.66%)
Abbott Laboratories operates in four diversified businesses: diagnostics, medical devices, nutrition, and established pharmaceuticals. This diversification limits the negative impact on growth if one area faces headwinds. In the fourth quarter, excluding the impact of coronavirus testing, sales climbed 10% to $11 billion. As a Dividend King, Abbott has increased its annual payment for more than 50 consecutive years, suggesting rewarding shareholders is important to the company. This, along with the fact that Abbott delivers more than $6 billion in free cash flow, indicates that Abbott will stick with its dividend policy.
3. Viking Therapeutics (VKTX 3.50%)
Viking Therapeutics is a biotech company working on potential treatments for metabolic and endocrine disorders, with a focus on weight-loss drug VK2735. VK2735 is a dual GIP/GLP-1 receptor agonist, a type of drug that interacts with hormones involved in the digestive process, and has generated promising results in trials so far. Viking stock soared last year when it first reported VK2735 results but has since given back a lot of those gains. Any positive trial news in the coming quarters and potential commercialization down the road could serve as major catalysts for share performance, making now a great time to get in on this high-potential stock.
In conclusion, Pfizer, Abbott Laboratories, and Viking Therapeutics stand out as "no-brainer" healthcare stocks to buy with $200 right now. These companies offer a mix of growth, stability, and potential for significant gains, making them attractive additions to any healthcare portfolio. By allocating your budget to these three stocks, you can diversify your portfolio and take advantage of the growth potential in the healthcare sector.
PFE--
VKTX--
Investing in healthcare stocks can be a lucrative strategy, given the sector's resilience and growth potential. With a $200 budget, you can diversify your portfolio by allocating funds to three promising healthcare stocks: Pfizer, Abbott Laboratories, and Viking Therapeutics. These companies offer a mix of growth, stability, and potential for significant gains.

1. Pfizer (PFE -0.35%)
Pfizer has taken major steps to turn around its business, including cost-cutting, acquiring and integrating oncology company Seagen, and investing in its internal pipeline. In the recent earnings report, Pfizer reported double-digit quarterly revenue growth, said it was on track to deliver cost savings of $4.5 billion by the end of the year, and reaffirmed its 2025 annual guidance. Pfizer is trading at only 8 times forward earnings estimates, making it an attractive addition to any healthcare portfolio.
2. Abbott Laboratories (ABT 0.66%)
Abbott Laboratories operates in four diversified businesses: diagnostics, medical devices, nutrition, and established pharmaceuticals. This diversification limits the negative impact on growth if one area faces headwinds. In the fourth quarter, excluding the impact of coronavirus testing, sales climbed 10% to $11 billion. As a Dividend King, Abbott has increased its annual payment for more than 50 consecutive years, suggesting rewarding shareholders is important to the company. This, along with the fact that Abbott delivers more than $6 billion in free cash flow, indicates that Abbott will stick with its dividend policy.
3. Viking Therapeutics (VKTX 3.50%)
Viking Therapeutics is a biotech company working on potential treatments for metabolic and endocrine disorders, with a focus on weight-loss drug VK2735. VK2735 is a dual GIP/GLP-1 receptor agonist, a type of drug that interacts with hormones involved in the digestive process, and has generated promising results in trials so far. Viking stock soared last year when it first reported VK2735 results but has since given back a lot of those gains. Any positive trial news in the coming quarters and potential commercialization down the road could serve as major catalysts for share performance, making now a great time to get in on this high-potential stock.
In conclusion, Pfizer, Abbott Laboratories, and Viking Therapeutics stand out as "no-brainer" healthcare stocks to buy with $200 right now. These companies offer a mix of growth, stability, and potential for significant gains, making them attractive additions to any healthcare portfolio. By allocating your budget to these three stocks, you can diversify your portfolio and take advantage of the growth potential in the healthcare sector.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios